BO‘LMACHALAR FIBRILLYATSIYASINI SHOSHILINCH DAVOLASH STRATEGIYASI VA TAKTIKASI: MUAMMONING ZAMONAVIY KO‘RINISHI
Keywords:
Bo‘lmachalar fibrillyatsiya, shoshilinch terapiya, elektr kardioversiya, elektr impuls terapiyasi, farmakologik kardioversiya, antiaritmik dorilar.Abstract
Bo‘lmachalar fibrillyatsiya (BF) eng keng tarqalgan taxiaritmiya bo‘lib, umumiy populyatsiyada 1,0-2,0% ni tashkil qiladi. Bu barcha insultlarning 20% sababidir va o‘limning ortishi va surunkali yurak etishmovchiligi xavfi bilan bog‘liq. BF ning paroksizmlari ko‘pincha bemorning ahvolining yomonlashishi, gemodinamik beqarorlik bilan birga keladi, bu shoshilinch tibbiy yordamni talab qiladi. Maqolada BF hujumlarini to‘xtatish strategiyasi va taktikasi, farmakologik kardioversiya va elektr impuls terapiyasiga ko‘rsatmalar haqida zamonaviy ko‘rinish berilgan. Taqdim etilgan material BF bilan og‘rigan bemorlarni boshqarish bo‘yicha xalqaro tavsiyalarga, shuningdek, bir qator zamonaviy nazorat qilinadigan tadqiqotlar ma’lumotlariga va aritmiyalarni davolash bo‘yicha o‘z klinik tajribamizga asoslangan. Shu bilan birga, maqola BFni shoshilinch davolashning ba’zi munozarali masalalarini ko‘rib chiqadi va aritmologiyaning ushbu sohasidagi bir qator tadqiqotlar natijalariga asoslangan.
References
Guidelines for the management of atrial fibrillation. Eur Heart J doi: 10.1093 /eurheart/ ehq 278.
2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation. Http://circ.ahajournals.org/content/early/2014/04/10/CIR.
Constantini O, Stambler B. Approach to the patients with atrial fibrillation. In Gans L.I, Braunwald E (eds). Management of cardiac arrhythmias. Hymana Press 2004; p. 75–96.
Khan IA. Single oral loading dose of propafenonefor pharmacological cardioversion of recent onset atrial fibrillation. J Am Coll Cardiol 2001; 37: 542–7.
Bunin Yu, Anfalova L. Efficacy of propafenone as single oral loading dose in pharmacology converting recent-onset atrial fibrillation and atrial flutter. Europace 2005; 7 (Suppl. 1): 121–2.
Chevalier P, Durand-Dubief A, Burri H. Amiodarone versus placebo and class IC drugs cardioversion of recent-onset atrial fibrillation: a meta-analysis. JACC 2003; 41: 255–61.
Rho RW, Callans DJ. The management of atrial flutter. In Gans L.I., Braunwald E. (eds). Management of cardiac arrhythmias. Hymana Press 2004; p. 163–82.
Camm AJ, Capucci A, Hohnloser S et al. A randomized active-controlled study comparing the efficacy and safety of vernacalant to amiodarone in recent onset atrial fibrillation. J Am Coll Cardiol 2010; 4: 134–9.
Sung RJ, Tan HL, Karagounis L et al. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter. Am Heart J 1995; 129: 739–48.
ESC guidelines 2011 on management of cardiovascular disease during pregnancy. Doi:10.1093/eurheartj/ehr 218.
American heart association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2005; 112: IV1–211.
Niebauer MJ, Brewer JE, Clung MK et al. Comparison of the rectilinear biphasic waveform with monophasic damped sine waveform for external cardioversion of atrial fibrillation and flutter. Am J Cardiol 2004; 93: 1495–9.
Ricard P, Vaici K, Rinaldi JP et al. Cardioversion of atrial fibrillation: how and when? Eur Heart J 2003; 5 (Suppl. H): H40–H44.
Botto GL, Politi A, Bonini W et al. External cardioversion of atrial fibrillation: role of paddle position on technical efficacy and energy requirements. Heart 1999; 82: 726–30. 15. European heart rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625–51.
